Table 1.
Baseline characteristics of the study population (N = 92)
| Variable | Value (mean±SD, median [IQR], or number [%]) | |
|---|---|---|
| Age, years | 65.6±10.9 | |
| Sex | Male | 74 (80.4) |
| Female | 18 (19.6) | |
| Body weight, kg | 64.5±10.6 | |
| BH, cm | 164.4±7.5 | |
| BMI, kg/m2 | 23.8±3.3 | |
| HBV related | 60 (65.2) | |
| HCV related | 18 (19.6) | |
| Alanine aminotransferase, U/L | 49±44 | |
| Albumin, g/dL | 4.3±0.5 | |
| Total bilirubin, mg/dL | 0.95±0.55 | |
| ALBI grade | 1 | 55 (59.8) |
| >1 | 37 (40.2) | |
| MELD sore | 8±2 | |
| Maximal tumor size, cm | 7.5±4.2 | |
| Tumor size, cm | ≤5 | 30 (32.6) |
| >5 | 62 (67.4) | |
| Tumor number | 1 | 29 (31.5) |
| 2–5 | 39 (42.4) | |
| >5 | 24 (26.1) | |
| Tumor distribution | Unilobar | 47 (51.1) |
| Bilobar | 45 (48.9) | |
| Total tumor volume, mL | 252 (405) | |
| Non-tumor liver volume, mL | 1,151±359 | |
| AFP, ng/mL | ≤400 | 52 (56.5) |
| >400 | 40 (43.5) | |
| BCLC stage | B | 52 (56.5) |
| C | 40 (43.5) | |
| ECOG performance status | 0 | 81 (88.0) |
| 1 | 11 (12.0) | |
| Administered activity (GBq) | 1.47±0.74 | |
| Prior therapy | 64 (69.6) | |
| 1-month objective response | 43 (46.7) | |
| 4-month objective response | 43 (46.7) | |
| 7-month objective response | 28 (30.4) | |
| Posttreatment curative therapy | 19 (20.7) |
SD, standard deviation; IQR, interquartile range; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group.